Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Friday. The firm issued a buy rating on the stock.

Trinity Biotech Price Performance

Shares of NASDAQ:TRIB opened at $1.99 on Friday. The firm has a market capitalization of $15.17 million, a PE ratio of -0.71 and a beta of 1.30. The business has a 50-day moving average of $2.55 and a two-hundred day moving average of $2.22. Trinity Biotech has a 12 month low of $1.49 and a 12 month high of $4.59.

Trinity Biotech (NASDAQ:TRIB) last posted its earnings results on Wednesday, August 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.10. The company had revenue of $15.84 million during the quarter, compared to analyst estimates of $15.75 million. As a group, research analysts anticipate that Trinity Biotech will post -1.91 earnings per share for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.